Trial Profile
Neoadjuvant IntraviTreal Ranibizumab treatment in high-risk Ocular melanoma patients: a two-stage single-centre phase II single arm study (NITRO trial)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2022
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- Acronyms NITRO - Version 1
- 01 Feb 2020 This study was terminated early as alternative treatments were clearly superior for local tumour control as per results published in the Melanoma Research
- 07 Jun 2018 Status changed to discontinued.
- 08 Nov 2013 Accrual to date is 28% according to United Kingdom Clinical Research Network record.